NCT06350630View on ClinicalTrials.gov

Therapeutic Effect of Hydroxychloroquine on Immunoglobulin A (IgA) Nephropathy Course QUIgAN Study

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

334

Participants

Timeline

Start Date

June 30, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2030

Conditions
IgA Nephropathy
Interventions
DRUG

Hydroxychloroquine Oral Tablet

Active hydroxychloroquine once daily by oral route at 6.5 mg/kg of ideal weight/day, with maximal dose of 400mg/day for 3 years

DRUG

Placebo oral tablet

placebo once daily by oral route (no active drug - same dosage as hydroxychloroquine )

Trial Locations (7)

13385

AP-HM Hôpital de la Conception, Marseille

42055

CHU de Saint-Etienne, Saint-Etienne

63000

CHU Gabriel Montpied, Clermont-Ferrand

69437

Hospices Civils de Lyon, Lyon

69495

CHU Lyon Sud, Pierre-Bénite

75018

APHP Hôpital Bichat, Paris

75020

APHP Hôpital de Tenon, Paris

All Listed Sponsors
collaborator

Ministry of Health, France

OTHER_GOV

lead

Centre Hospitalier Universitaire de Saint Etienne

OTHER